ATE553778T1 - Für humanes hepcidin spezifische antikörper - Google Patents

Für humanes hepcidin spezifische antikörper

Info

Publication number
ATE553778T1
ATE553778T1 AT08835406T AT08835406T ATE553778T1 AT E553778 T1 ATE553778 T1 AT E553778T1 AT 08835406 T AT08835406 T AT 08835406T AT 08835406 T AT08835406 T AT 08835406T AT E553778 T1 ATE553778 T1 AT E553778T1
Authority
AT
Austria
Prior art keywords
antibodies specific
human hepcidin
hepcidin
human
antigen
Prior art date
Application number
AT08835406T
Other languages
English (en)
Inventor
Sophie Vaulont
Hugues Gascan
Josy Froger
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE553778T1 publication Critical patent/ATE553778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08835406T 2007-10-02 2008-10-02 Für humanes hepcidin spezifische antikörper ATE553778T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291196 2007-10-02
PCT/IB2008/003310 WO2009044284A1 (en) 2007-10-02 2008-10-02 Antibodies specific for human hepcidin

Publications (1)

Publication Number Publication Date
ATE553778T1 true ATE553778T1 (de) 2012-05-15

Family

ID=38983917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08835406T ATE553778T1 (de) 2007-10-02 2008-10-02 Für humanes hepcidin spezifische antikörper

Country Status (8)

Country Link
US (1) US8487081B2 (de)
EP (1) EP2200647B1 (de)
JP (1) JP2010539969A (de)
CN (1) CN101903044A (de)
AT (1) ATE553778T1 (de)
CA (1) CA2701694A1 (de)
ES (1) ES2385772T3 (de)
WO (1) WO2009044284A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2186524B1 (de) † 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Hepcidin als ein Regler der Eisenhomöostase
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
PE20091261A1 (es) 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
WO2009139822A1 (en) * 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) * 2008-08-06 2013-09-10 Елі Ліллі Енд Компані Селективні антитіла проти гепсидину-25 та їх застосування
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
CN102574805A (zh) 2009-08-20 2012-07-11 维福（国际）股份公司 新型喹啉铁调素拮抗剂
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JPWO2022154121A1 (de) * 2021-01-18 2022-07-21

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP2186524B1 (de) 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Hepcidin als ein Regler der Eisenhomöostase
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
EP1578254B1 (de) * 2002-11-19 2013-03-06 DRG International, Inc. Diagnoseverfahren für erkrankungen durchuntersuchung auf hepcidin in menschlichem oder tierischem gewebe, blut oderkörperflüssigkeiten und therapeutische anwendungen dafür
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper

Also Published As

Publication number Publication date
US20100285027A1 (en) 2010-11-11
CA2701694A1 (en) 2009-04-09
US8487081B2 (en) 2013-07-16
EP2200647B1 (de) 2012-04-18
ES2385772T3 (es) 2012-07-31
EP2200647A1 (de) 2010-06-30
CN101903044A (zh) 2010-12-01
JP2010539969A (ja) 2010-12-24
WO2009044284A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CU24058B1 (es) Antagonistas de pcsk9
EA201370081A1 (ru) Антитела к cd48 и их применение
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
ECSP10010270A (es) Anticuerpos bivalentes biespecíficos
JO3097B1 (ar) الأجسام المضادة c-Met
BR112012007365A2 (pt) proteínas de ligação à il-1
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
EA201790757A1 (ru) Связывающие антиген cd27l белки
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
MY177564A (en) Anti-nr10 antibody and use thereof
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
CR20110400A (es) Proteinas de enlace al receptor cgrp humano